AGNES KWAPONG-AYEH: Open Payments
NPI 1841676483 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$555 in 9 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $529 · 2025 $555
Food & beverage: $555
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $97 |
| Luye Pharma (USA) Ltd. | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: REXULTI, CAPLYTA, ERZOFRI EXTENDED-RELEASE, TRINTELLIX, Qelbree.
Industry payments across TX — which companies pay providers there.
